ArticleDrug and alcohol dependence2021
Medical provider stigma experienced by people who use drugs (MPS-PWUD): Development and validation of a scale among people who currently inject drugs in New York City.
Article in Drug and alcohol dependence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Does perceived stigma impact opioid use disorder treatment uptake? A cross-sectional secondary analysis of buprenorphine engagement among syringe service program participants.Addiction science & clinical practice · 2026Trial
- Reduced injection risk behavior with co-located hepatitis C treatment at a syringe service program: The accessible care model.PloS one · 2024Trial
- Accessible Hepatitis C Care for People Who Inject Drugs: A Randomized Clinical Trial.JAMA internal medicine · 2022Trial
- The impact of COVID-19 on people who inject drugs in New York City: increased risk and decreased access to services.Harm reduction journal · 2021Trial
- "We're All in This Together": A Mixed-Methods Study of Provider and Patient Perceptions of Emergency Care for Opioid Use Disorder.Journal of advanced nursing · 2026Observational
- "I really can't imagine anything that could've been more easy": patient perspectives on low-threshold peer-facilitated telemedicine hepatitis C treatment for people who use drugs.Addiction science & clinical practice · 2026Article
- Zeroing in on xylazine - a mixed methods study to explore correlates of reported xylazine use and educational gaps among people who use drugs.Harm reduction journal · 2026Article
- Article
- Article
- Long-Term Benefits Following Hepatitis C Cure Through Facilitated Telemedicine; Experiences of People With Opioid use Disorder Five Years After Achieving a Sustained Virological Response.Health expectations : an international journal of public participation in health care and health policy · 2025Article
- "There's a lot of people who love them, so why call 'em junkies?": clinician and patient perspectives about words used to describe people who use drugs.Addiction science & clinical practice · 2025Article
- Understanding motives for illicit medicinal cannabis use: an exploratory analysis in a medical cannabis program.Journal of cannabis research · 2025Article
- Testing the Relationships Between Multiple Domains of Substance Use‑Related Stigma and Depression Among a Sample of Young (18-30‑Year‑Old) People Who Inject Drugs in the Greater Chicago Area.International journal of mental health and addiction · 2025Article
- Predicting fatal opioid-involved overdoses: A social-ecological framework matched to a linked-data warehouse.The International journal on drug policy · 2025Article
- Drug-related stigma among people who inject drugs - development and validation of the drug use stigma scale (DUSS).PloS one · 2025Article
- Factors Shaping Medical Student Attitudes Toward Harm Reduction.PRiMER (Leawood, Kan.) · 2025Article
- Overdose response centering inequity and diversity study: a protocol for assessing the population-level and equity impact of the emergency medical services system changes using critical race theory.Frontiers in public health · 2025Article
- How post overdose response efforts can address social determinants of health among people who use drugs: perspectives from the New York State Department of Health (NYSDOH) Post Overdose Response Team (PORT).Harm reduction journal · 2024Review
- Providers' knowledge and perception of xylazine in the unregulated drug supply: a sequential explanatory mixed-methods study.Harm reduction journal · 2024Article
- "It's Like A Partnership": Exploring the Primary Care Experiences and Patient-Defined Goals of People Who Use Drugs.Journal of general internal medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundStigmatizing attitudes towards people who use drugs (PWUD) impact their access and retention in health care. Current measures of PWUD stigma in medical settings are limited. Therefore, we developed and validated theMedical Provider Stigma Experienced by PWUD (MPS-PWUD) scale.
methodsAs part of an ongoing clinical trial, we recruited HCV RNA positive people who inject drugs in New York City. Based on 164 participants, principal component analysis (PCA) was conducted on fifteen stigma items answered on a 5-point Likert scale. We evaluated internal consistency using Cronbach's alpha coefficient and assessed construct validity by comparing stigma levels with willingness to communicate health concerns with medical providers and likelihood to seek HCV treatment.
resultsPCA identified a 9-item scale with two components of stigmatization that explained 60.8 % of the total variance and overall high internal consistency (alpha = 0.90). Theenacted stigma (alpha = 0.90) consisted of 6 scale items related to the medical providers' stigmatizing actions or perceptions. The internalized stigma component (alpha = 0.84) included 3 scale items related to PWUD's shame or drug use disclosure. As hypothesized, higher levels of either stigma were associated with less likelihood to openly communicate with medical providers (p < 0.005). Participants with a higher level of enacted stigma were less likely to seek HCV treatment (p = 0.011).
conclusionsThe validated MPS-PWUD scale could help healthcare providers, harm reduction services and researchers measure stigma experienced by PWUD in medical settings in efforts to minimize the impact of stigma on limiting access to and retention of care for PWUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.